3/28
07:30 am
huma
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Medium
Report
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
3/26
10:50 am
huma
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
3/26
08:00 am
huma
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
Low
Report
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
3/25
08:35 pm
huma
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
High
Report
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
3/25
04:01 pm
huma
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
High
Report
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
3/12
08:15 am
huma
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Low
Report
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
3/10
11:18 am
huma
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics [Yahoo! Finance]
Low
Report
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics [Yahoo! Finance]
3/10
08:00 am
huma
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
Low
Report
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
3/7
12:32 pm
huma
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
3/6
08:45 am
huma
Trestle Bio Announces Research Collaboration with Humacyte [Yahoo! Finance]
Low
Report
Trestle Bio Announces Research Collaboration with Humacyte [Yahoo! Finance]
3/6
08:00 am
huma
Trestle Bio Announces Research Collaboration with Humacyte
Low
Report
Trestle Bio Announces Research Collaboration with Humacyte
3/3
08:06 am
huma
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 [Yahoo! Finance]
High
Report
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 [Yahoo! Finance]
3/3
08:00 am
huma
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
High
Report
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
2/27
04:05 pm
huma
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
Low
Report
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
2/27
10:50 am
huma
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at Benchmark Co..
High
Report
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at Benchmark Co..
2/27
08:08 am
huma
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues [Yahoo! Finance]
Medium
Report
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues [Yahoo! Finance]
2/27
08:00 am
huma
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
Medium
Report
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
2/26
08:36 am
huma
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
2/26
08:00 am
huma
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
High
Report
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
1/28
08:00 am
huma
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
Low
Report
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
1/25
03:07 am
huma
https://seekingalpha.com/article/4751968-humacyte-upside-potential-i-will-wait-for-revenue-trends [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4751968-humacyte-upside-potential-i-will-wait-for-revenue-trends [Seeking Alpha]
1/23
09:00 pm
huma
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
1/21
09:59 am
huma
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
Humacyte, Inc. (NASDAQ: HUMA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
1/21
08:00 am
huma
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
Medium
Report
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
1/17
04:15 pm
huma
January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA
Medium
Report
January 17, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against HUMA